Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 3, 2008

GSK and the Immune Disease Institute in Boston Sign Five-Year $25M Collaboration

  • GlaxoSmithKline (GSK) signed a five-year collaboration with the Immune Disease Institute in Boston (IDI) worth $25M to accelerate research in immunoinflammation.

    IDI’s immunological expertise will be combined with GSK’s pharmaceutical capabilities. This partnership allows researchers at both institutions to develop joint grant proposals under what will be called the Alliance Research grant program.

    Additionally, GSK receives an exclusive right of first negotiation for a substantial portion of the new technologies discovered and disclosed by IDI scientists during the term of the agreement. The research will be anchored through GSK’s Immuno-Inflammation Centre of Excellence in Drug Discovery.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »